Fused heterocyclic benzenecarboxamide derivatives and PGD.sub.2

Details Fused heterocyclic benzenecarboxamide derivatives and PGD.sub.2 Fused heterocyclic benzenecarboxamide derivatives and PGD.sub.2

1999-05-28

2000-05-30

Lambkin, Deborah C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

514468, 514469, 549 43, 549 57, 549461, 549470, A61K 3138, A61K 3134, C07D33374, C07D33356, C07D30791

Patent

active

060691662

DESCRIPTION:

BRIEF SUMMARY
FIELD OF THE INVENTION

The present invention relates to fused heterocyclic benzenecarboxamide derivatives, pharmaceutical compositions comprising them, PGD.sub.2 (prostaglandin D.sub.2) antagonists comprising them and drugs for treating nasal blockage comprising them.


BUCKGROUND OF THE INVENTION

Some of bicyclic amide derivatives analogous to the compounds of the present invention have been described as thromboxane A.sub.2 (TXA.sub.2) antagonists (Japanese Patent Publication (Kokoku) No. 53295/1991). However, in the Japanese Patent Publication (Kokoku) No. 53295/1991, it has only been described that the compounds are useful as TXA.sub.2 antagonists, but there is no suggestion of usefulness thereof as PGD.sub.2 antagonists as found in the present invention. On the other hand, in Japanese Patent Publication (Kokoku) No.79060/1993, Japanese Patent Publication (Kokoku) No.23170/1994 and Chem. Pharm. Bull. Vol.37, No.6 1524-1533 (1989), bicyclic amide derivatives have been described as intermediates for bicyclic sulfonamide derivatives. However, the compounds disclosed therein are different from those of the present invention in the types of substituents at the amide portion. And some of the compounds analogous to the compounds of the present invention have been described as PGD.sub.2 antagonists in WO 97/00853. However, there is no suggestion that the compounds disclosed in WO 97/00853 possess a inhibitory activity against infiltration of eosionophils.
TXA.sub.2 has been known to have various activities such as platelet aggregation, thrombogenesis, etc. The TXA.sub.2 antagonists which compete with TXA.sub.2 have therefore been considered to be useful as anti-thrombotic agents as well as medicines to be used in the treatment of myocardial infarction or asthma. On the other hand, the PGD.sub.2 antagonists of the present invention are useful for the improvement of conditions caused by excessive production of PGD.sub.2, particularly as drugs for treating diseases in which mast cell dysfunction is involved, for example, systemic mastocytosis and disorder of systemic mast cell activation as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, ischemic reperfusion injury, inflammation, and atopic dermatitis.
PGD.sub.2 is a major prostanoid that is produced in and released from mast cells in which it is produced through PGG.sub.2 and PGH.sub.2 from arachidonic acid by the action of cyclooxygenase activated by immunological or unimmunological stimulation. PGD.sub.2 has various potent physiological and pathological activities. For example, PGD.sub.2 can cause strong tracheal contraction to lead to bronchial asthma, and in a systemic allergic state, it dilates the peripheral vessels to cause an anaphylactic shock. Especially, much attention has been paid to the theory that PGD.sub.2 is one of the causal substances responsible to the onset of nasal blockage in the allergic rhinitis. Therefore, it has been proposed to develop an inhibitor against the biosynthesis of PGD.sub.2 or an antagonist of PGD.sub.2 receptor as a drug for the reduction of nasal blockage. However, the inhibitor of PGD.sub.2 biosynthesis possibly much affects the synthesis of prostaglandins in other parts of organisms, and therefore, it is desirable to develop an antagonist (blocker) specific to the PGD.sub.2 receptor.


DISCLOSURE OF THE INVENTION

The present inventors have studied intensively to develop PGD.sub.2 receptor antagonists (blockers) specific to the PGD.sub.2 receptor, and found that a series of compounds of the formula (I) below, pharmaceutically acceptable salts thereof, or hydrates thereof possess a potent activity as PGD.sub.2 receptor antagonists and a inhibitory activity against infiltration of eosionophils, and are useful as drugs for treating nasal blockage. The compounds of the present invention having PGD.sub.2 antagonist activity are different from the known TXA.sub.2 antagonists in the active site and mechanism, application, and character.
Accordingly, the present invention provides

REFERENCES:
patent: 4389413 (1983-06-01), Hamanaka et al.
patent: 4792550 (1988-12-01), Miyake et al.
patent: 4904819 (1990-02-01), Hagishita et al.
patent: 5168101 (1992-12-01), Arai et al.
patent: 5728846 (1998-03-01), Vuligonda et al.
patent: 5763609 (1998-06-01), Yuan et al.
patent: 5929107 (1999-07-01), Natsugari et al.
Seno, K., et al., "Thromboxane A.sub.2 Receptor Antagonist. III. Synthesis and Pharmacological Activity of 6,6-Dimethylbicyclo[3.1.1]heptane Derivatives with a Substituted Sulfonylamino Group at C-2", Chem. Pharm. Bull., vol. 37, No. 6, pp. 1524-1533 (1989).
Tsuri, T., et al., "Bicyclo[2.2.1]heptane and 6,6-Dimethylbicyclo[3.1.1]heptane Derivatives: Orally Active, Potent, and Selective Prostaglandin D.sub.2 Receptor Antagonists," J. Med. Chem., vol. 40, pp. 3504-3507 (1997).
Martin-Smith, M., et al., "Benzo[.beta.]thiophen Derivatives. Part VI. The Syntheses of 3-(2-Amino-ethyl)-5-hydroxybenzo[.beta.]thiophen and Related Compounds," J. Chem. Soc., Section C, pp. 1898-1905 (1967).

Affiliated with

Also associated with

Rating

Fused heterocyclic benzenecarboxamide derivatives and PGD.sub.2 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fused heterocyclic benzenecarboxamide derivatives and PGD.sub.2 , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic benzenecarboxamide derivatives and PGD.sub.2 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1910727